Alan Swaisland

Metabolic activation of benzo(a)pyrene proceeds by a diol-epoxide

Peter Sims, P.L. Grover, Alan Swaisland et al. · Nature · 1974 · 1.1K citations

Life Sciences, Biochemistry, Metabolism +12

Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck

J.S.W. Stewart, Ezra E.W. Cohen, Lisa Licitra et al. · Journal of Clinical Oncology · 2009 · 380 citations

Medicine, Oncology, Pharmacology +10

Phase 1 Trial of Gefitinib Plus Sirolimus in Adults with Recurrent Malignant Glioma

David A. Reardon, Jennifer A. Quinn, James J. Vredenburgh et al. · Clinical Cancer Research · 2006 · 192 citations

Medicine, Oncology, Pharmacology +17

Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial

R.A. Hannon, Glen Clack, Martin Rimmer et al. · Journal of Bone and Mineral Research · 2009 · 110 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors

José Baselga, Andrés Cervantes, Erika Martinelli et al. · Clinical Cancer Research · 2010 · 109 citations

Medicine, Oncology, Pharmacology +15